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This thesis presents findings from two randomised, controlled pilot studies, with 
nested sub-studies, an observational study, a compassionate release 
programme and a mortality audit. It aims to examine the effects, at a clinical 
and cellular level, of antiretroviral and immunotherapy in HIV-1 infection. 
Combination antiretroviral therapy (cART) enables quantitative and a degree 
of qualitative immune recovery; however this is neither universal nor complete. 
The first part of the thesis explores the effects of cART on surrogate immune 
markers (SIM), treatment outcomes, disease progression and death. Significant 
variations are observed and further re-inforced by the mortality audit. I 
describe for the first time patterns of SIM decline and treatment response from 
which a model predicting treatment outcome could be developed. This 
section concludes with an observational study describing a differential effect 
on immune restoration of different classes of cART. Together this data suggests 
additional therapeutic interventions will be required to address the current 
inadequacies of cART to fully restore HIV-1 associated immune deficiencies. 
Therefore, the second part of the thesis examines the effect of interleukin-2 (IL-
2) therapy in different settings; with and without cART, with therapeutic 
immunisation and in advanced disease. In the absence of cART, IL-2 increased 
CD4 T-cell counts without adversely affecting viral load or immune activation, 
potentially delaying the need for cART initiation. The compassionate release 
programme also demonstrated a ‘delaying’ effect which could be exploited 
in patients awaiting new therapies. The main therapeutic intervention study 
involved IL-2 and therapeutic immunisation in the context of cART, and reports 
novel findings of the acute effects of IL-2, including induction of HIV-1 specific 
responses. Overall increases were observed in CD4+, CD4+CD28+ and 
CD4+CD25+ T-cells, the latter being of particular interest as the precise 
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function of these cells in HIV-1 infection and following IL-2 therapy is still to be 
fully defined. As a pilot study these findings are preliminary but there is a trend 
for several effects to be more marked and more sustained in the arm combing 
all three treatments; suggesting therapeutic potential for combination 
immunisation and cytokine therapy which is worth pursuing. Despite the fact 
that the final IL-2 study in this thesis was completed in 2003, the recent 
publication of two large clinical outcome studies of IL-2, with somewhat 
unexpected results, makes these findings all the more pertinent today, and 
may afford some insight into the negative results observed in these large phase 
three trials. In summary, cART results in incomplete immune reconstitution, 
which can be enhanced by IL-2 and therapeutic immunisation at a cellular 
level. The challenge is to determine how, if at all, this can be translated into 
clinical benefit. Using additional SIM may help in targeting and monitoring 
therapy; the timing, scheduling and combination of which will be key and 
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PBS  Phosphate buffered saline 
PCL  Primary cerebral lymphoma 
PCP  Pneumocystis cariniii pneumonia 
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PHI  Primary HIV-1  infection 
PI  Protease inhibitor 
PPD  Purified protein derivative 
PWM  Pokeweed mitogen 
RNA  Ribonucleic acid 
QOL  Quality of life 
RCT  Randomised control trial 
rIL-2  Recombinant human interleukin-2 
SD  Standard deviation 
SE  Standard error 
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sIL-2  Soluble IL-2 receptors 
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TH1  T helper type 1 
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